PolyPid Announces Presentation of Clinical Data at Surgical Infection Society 2022 Annual Meeting

Rhea-AI Summary

PolyPid Ltd. (Nasdaq: PYPD) announced plans to present clinical data evaluating the addition of D-PLEX100 to standard infection prophylaxis in elective colorectal surgery. This presentation will occur at the Surgical Infection Society 2022 Annual Meeting on April 23-26, 2022. The study titled ‘Incisional microenvironments and reduction in SSIs in patients treated with a local doxycycline-eluting formulation’ will be led by Dr. Anthony Senagore. PolyPid aims to enhance surgical outcomes through its proprietary PLEX technology, with D-PLEX100 currently in Phase 3 trials.

Positive

• Presentation of clinical data at a significant medical conference.
• Potential to enhance surgical outcomes with D-PLEX100.
• D-PLEX100 is in Phase 3 clinical trials, indicating advanced development stage.

Negative

• None.

Presentation evaluates the addition of D-PLEX₁₀₀ to the surgical site infection standard of care prophylaxis regimen in elective colorectal surgery

PETACH TIKVA, Israel, April 12, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, announced today that the Company will present clinical data at the upcoming Surgical Infection Society (SIS) 2022 Annual Meeting, being held on April 23-26, 2022 in Dallas, TX.

The abstract, ‘Incisional microenvironments and reduction in SSIs in patients treated with a local doxycycline-eluting formulation,’ evaluates the addition of D-PLEX₁₀₀ to the surgical site infection standard of care prophylaxis regimen in elective colorectal surgery. The presentation will include an oral review led by Dr. Anthony Senagore, Senior Medical Director of PolyPid, and will be available on https://www.polypid.com/ following the presentation.

About PolyPid

PolyPid Ltd. (Nasdaq: PYPD) is a late-stage biopharma company aiming to improve surgical outcomes. Through locally administered, controlled, prolonged-release therapeutics, PolyPid’s proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with Active Pharmaceutical Ingredients, enabling precise delivery of drugs at optimal release rates over durations ranging from several days to months. PolyPid’s lead product candidate D-PLEX100 is in Phase 3 clinical trials for the prevention of soft tissue abdominal and sternal bone surgical site infections. In addition, the company is currently in preclinical stages to test the efficacy of OncoPLEX for treatment of solid tumors, beginning with glioblastoma. For additional company information, please visit http://www.polypid.com and follow us on Twitter and LinkedIn.

References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. PolyPid is not responsible for the contents of third-party websites.

Corporate Contact:

PolyPid Ltd.
Dikla Czaczkes Akselbrad
EVP & CFO
Tel: +972-747195700

Investor Contact:
Bob Yedid
LifeSci Advisors
646-597-6989
Bob@LifeSciAdvisors.com

Media Contact:
Nechama Feuerstein
FINN Partners
551-444-0784
Nechama.Feuerstein@finnpartners.com

FAQ

What is D-PLEX100 and its significance in colorectal surgery for PolyPid (PYPD)?

D-PLEX100 is a drug formulation aimed at reducing surgical site infections (SSIs) during elective colorectal surgery. Its evaluation suggests it may enhance standard care protocols.

When will PolyPid present its clinical data related to D-PLEX100?

PolyPid will present clinical data at the Surgical Infection Society 2022 Annual Meeting from April 23-26, 2022.

What are the potential market impacts of D-PLEX100 for PolyPid (PYPD)?

If successful, D-PLEX100 could improve surgical outcomes, potentially increasing market adoption and revenue for PolyPid.

What are the next steps after the presentation of D-PLEX100 by PolyPid?

Following the presentation, PolyPid may continue to seek regulatory approvals and move towards commercialization based on trial results.